Rekombinanter GPIIb/IIIa (Abciximab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter GPIIb/IIIa (Abciximab Biosimilar) Antikörper (ABIN7795100)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody
-
Produktmerkmale
- Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab. Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor. While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human Glycoprotein IIb/IIIa Receptor
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- GPIIb/IIIa (Abciximab Biosimilar)
-
Andere Bezeichnung
- Abciximab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-